Rho-kinase inhibitors in the management of glaucoma

References

• Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Quigley HA. Glaucoma. Lancet. 2011;377:1367–1377.
   PubMed Web of Science ®Google Scholar
• Johnson M. What controls aqueous humour outflow resistance? Exp Eye Res. 2006;82:545–557.
   PubMed Web of Science ®Google Scholar
• Gabelt BAT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24:612–637.
   PubMed Web of Science ®Google Scholar
• Keller KE, Aga M, Bradley JM, et al. Extracellular matrix turnover and outfow resistance. Exp Eye Res. 2009;88:676–682.
   PubMed Web of Science ®Google Scholar
• Kameda T, Inoue T, Inatani M, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm’s canal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53:3092–3103.
   PubMed Web of Science ®Google Scholar
• Nakajima E, Nakajima T, Minagawa Y, et al. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outfow in monkey and human eyes. J Pharma Sci. 2005;94:701–708.
   PubMed Web of Science ®Google Scholar
• Stamer WD, Acott TS. Current understanding of conventional outflow dysfunction in glaucoma. Curr Opin Ophthalmol. 2012;23:135–143.
   PubMed Web of Science ®Google Scholar
• Fingeret M, Mancil GL, Bailey IL, et al. Optometric clinical practice guideline care of the patients with open angle glaucoma. American Optometric Association. Revised. 2010 [Cited 2018 Jul 12]. Available from: https://www.aoa.org/documents/optometrists/CPG-9.pdf
   Google Scholar
• Kerty E, Hørven I. Glaucoma treatment with timolol. Acta Ophthalmol (Copenh). 1978;56:705–714.
   PubMed Web of Science ®Google Scholar
• Maren TH. The development of topical carbonic anhydrase inhibitors. J Glaucoma. 1995;4:49–62.
   PubMedGoogle Scholar
• Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost study groups. Ophthalmology. 1996;103:1916–1924.
   PubMed Web of Science ®Google Scholar
• Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997;6:250–258.
   PubMed Web of Science ®Google Scholar
• Kaufman PL, Barany EH. Loss of acute pilocarpine effect on outfow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol. 1976;15:793–797.
   PubMedGoogle Scholar
• Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211–2215.
   PubMed Web of Science ®Google Scholar
• Inazaki H, Kobayashi S, Anzai Y, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. JGlaucoma. 2017;26:96–100.
   PubMed Web of Science ®Google Scholar
• Kusuhara S, Katsuyama A, Matsumiya W, et al. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2018;256:809–814.
   PubMed Web of Science ®Google Scholar
• Saito H, Kagami S, Mishima K, et al. Long-term side effects including blepharitis leading to discontinuation of ripasudil. J Glaucoma. 2019;28:289–293.
   PubMed Web of Science ®Google Scholar
• Sakamoto E, Ishida W, Sumi T, et al. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial. Sci Rep. 2019;9:3755.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Netarsudil ophthalmic solution 0.02%: first global approval. Drugs. 2018;78:389–396.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: 3-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;19:30284–3.
   Google Scholar
• Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol. 2018;62:109–126.
   PubMed Web of Science ®Google Scholar
• Tanna AP, Johnson M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology. 2018;125:1741–1756.
   PubMed Web of Science ®Google Scholar
• Moura-Coelho N, Tavares Ferreira J, Bruxelas CP, et al. Rho kinase inhibitors—a review on the physiology and clinical use in ophthalmology graefes. Arch Clin Exp Ophthalmol. 2019;257:1101–1117.
   PubMed Web of Science ®Google Scholar
• Schehlein EM, Robin AL. Rho-associated kinase inhibitors: evolving strategies in glaucoma treatment. Drugs. 2019;79:1031–1036.
   PubMed Web of Science ®Google Scholar
• Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004;116:167–179.
   PubMed Web of Science ®Google Scholar
• Rossman KL, Der CJ, Sondek J. GEF means go: turning on Rho GTPases with guanine nucleotideexchange factors. Nat Rev Mol Cell Biol. 2005;6:167–180.
   PubMed Web of Science ®Google Scholar
• Bishop A, Rho HA. GTPases and their effector proteins. Biochem J. 2000;348:241–255.
   PubMed Web of Science ®Google Scholar
• Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for the small GTP binding protein Rho. Embo J. 1996;15:2208–2216.
   PubMed Web of Science ®Google Scholar
• Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189–193.
   PubMed Web of Science ®Google Scholar
• Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4:387–398.
   PubMed Web of Science ®Google Scholar
• Riento K, Ridley A. ROCKs: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Bio. 2003;4:446–456.
   PubMed Web of Science ®Google Scholar
• Loirand G. Rho kinases in health and disease: from basic science to translational research. Pharmacol Rev. 2015;67:1074–1095.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV, Defert O, et al. Rho kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem. 2016;59:2269–2300.
   PubMed Web of Science ®Google Scholar
• Tian B, Geiger B, Epstein DL, et al. Cytoskeletal involvement in the regulation of aqueous humor outfow. Invest Ophthalmol Vis Sci. 2000;41:619–623.
   PubMed Web of Science ®Google Scholar
• Tian B, Kaufman PL, Volberg T, et al. H-7 disrupts the actin cytoskeleton and increases outfow facility. Arch Ophthalmol. 1998;116:633–643.
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137–144.
   PubMed Web of Science ®Google Scholar
• Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216–3222.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective rock inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309–315.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:26–34.
   PubMed Web of Science ®Google Scholar
• Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302–307.
   PubMed Web of Science ®Google Scholar
• Hall J, Sall KN, Peace JH, et al. Initial clinical evaluation of safety, tolerability and pharmacodynamics of the locally-acting ROCK inhibitor AMA0076. Investig Opthalmol Vis Sci. 2014;55:565.
   Web of Science ®Google Scholar
• Inoue T, Tanihara H, Tokushige H, et al. Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 2015;93:393–395.
   PubMed Web of Science ®Google Scholar
• Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994.
   PubMed Web of Science ®Google Scholar
• Amakem NV. Novel ROCK inhibitors. WO2012146724. 2012.
   Google Scholar
• Feng Y, LoGrasso PV. Rho kinase inhibitors: a patent review (2012–2013). Expert Opin Ther Patents. 2014;24:295–297.
   PubMed Web of Science ®Google Scholar
• Defert O, Boland S. Rho kinase inhibitors: a patent review (2014–2016). Expert Opin Ther Pat. 2017;27:507–515.
   PubMed Web of Science ®Google Scholar
• Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39:813–822.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Ohta M, Inoue T, et al. Efects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep. 2016;6:19640.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731–736.
   PubMed Web of Science ®Google Scholar
• Kitaoka Y, Sase K, Tsukahara C, et al. Axonal protection by ripasudil, a rho kinase inhibitor, via modulating autophagy in TNF-induced optic nerve degeneration. Invest Ophthalmol Vis Sci. 2017;58:5056–5064.
   PubMed Web of Science ®Google Scholar
• Akaiwa K, Namekata K, Azuchi Y, et al. Topical ripasudil suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. Invest Ophthalmol Vis Sci. 2018;59:2080–2089.
   PubMed Web of Science ®Google Scholar
• Futakuchi A, Inoue T, Fujimoto T, et al. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107–115.
   PubMed Web of Science ®Google Scholar
• Kojima S, Sugiyama T, Takai S, et al. Effects of ripasudil, a Rho-associated protein kinase inhibitor, on conjunctival scarring in a canine fltration surgery model. Curr Top Pharmacol. 2015;19:67–73.
   Google Scholar
• Tanihara H, Kakuda T, Sano T, et al. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study. Adv Ther. 2019;36:333–343.
   PubMed Web of Science ®Google Scholar
• Boger WP. Shortterm. “escape” and longterm “drift”: the dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28:235–240.
   PubMedGoogle Scholar
• Kowa Co. Agent for enhancing ocular hypotensive effect. WO2017038856. 2017.
   Google Scholar
• Okamoto M, Nagahara M, Tajiri T, et al. Rho-associated protein kinase inhibitor induced morphological changes in type VI collagen in the human trabecular meshwork. Br J Ophthalmol. 2019;2018:312991.
   Google Scholar
• Trueb B, Schreier T, Bruckner P, et al. Type VI collagen represents a major fraction of connective tissue collagens. Eur J Biochem. 1987;166:699–703.
   PubMedGoogle Scholar
• Koudouna E, Young RD, Ueno M, et al. Three-dimensional architecture of collagen type VI in the human trabecular meshwork. Mol Vis. 2014;20:638–648.
   PubMed Web of Science ®Google Scholar
• Kowa CO. Drug therapy for preventing or treating glaucoma. WO2012105674. 2012.
   Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755–761.
   PubMed Web of Science ®Google Scholar
• Kowa CO. Pharmacotherapy for preventing or treating glaucoma. WO2016093348. 2016.
   Google Scholar
• Jiangsu Leeway Biological Tech Co. Hydrochloric acid ripasudil crystal form. CN106496189. 2017.
   Google Scholar
• Jiangsu Jibeier Pharmacy Stock Co. New ripasudil hydrochloride hydrate eye drop and preparation method thereof. CN106310285. 2017.
   Google Scholar
• Aerie Pharmaceuticals, Inc. Dual-action inhibitors and methods using the same. WO2010127330. 2010.
   Google Scholar
• Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds composition and use.WO2012012282. 2012.
   Google Scholar
• Abbvie Inc. NAMPT and ROCK inhibitors.WO2012067965. 2012.
   Google Scholar
• Sturdivant JM, Royalty SM, Lin CW, et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett. 2016;26:2475–2480.
   PubMed Web of Science ®Google Scholar
• Ren R, Li G, Le TD, et al. Netarsudil increases outfow facility in human eyes through multiple echanisms. Invest Ophthalmol Vis Sci. 2016;57:6197–6209.
   PubMed Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. Two Phase 3 clinical trials comparing the safety and efcacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–127.
   PubMed Web of Science ®Google Scholar
• Bacharach J, Khouri AS, Heah T, et al. A double-masked, randomized, multi-center, activecontrolled, parallel group, 6-month study assessing the ocular hypotensive efcacy and safety of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patie. Am Acad Optom Abst E351. 2017. (Oct 11–14, Chicago).
   Google Scholar
• Aerie Pharmaceuticals, Inc. Combination therapy. WO2014144781. 2014.
   Google Scholar
• Santen Pharmaceutical Co. Medicament comprising combination of sepetaprost and rho-kinase inhibitor. WO2019124488. 2019.
   Google Scholar
• Kadmon Corp. Rho kinase inhibitors. WO2015054317. 2015.
   Google Scholar
• Kadmon Corp. Inhibitors of Rho associated coiled-coil containing protein kinase. WO2019018853. 2019.
   Google Scholar
• Hitgen Ltd. Compound for inhibiting rock, preparation method and use of same. WO2017114275. 2017.
   Google Scholar
• Translational Drug Development. Heterocyclic compounds as kinase inhibitors. WO2016187324. 2016.
   Google Scholar
• Bristol-Myers Squibb Co. Tricyclic Rho kinase inhibitors. WO2018102325. 2018.
   Google Scholar
• Bristol-Myers Squibb Co. Tricyclic pyridocarboxamide derivatives as ROCK inhibitors and their preparation. WO2015002915. 2015.
   Google Scholar
• Univ Sichuan. Flavonoid derivative with ROCK kinase inhibiting effect. CN108558810. 2018.
   Google Scholar
• Baek I, Jeon SB, Song MJ, et al. Flavone attenuates vascular contractions by inhibiting RhoA/Rho kinase pathway. Korean J Physiol Pharmacol. 2009;13:201–207.
   PubMed Web of Science ®Google Scholar
• Alcon Inc. RNAi-mediated inhibition of ocular hypertension targets. WO2006084217. 2006.
   Google Scholar
• Fischer SE. RNA interference and microRNA-mediated silencing. Curr Protoc Mol Biol. 2015;112:26.
   PubMedGoogle Scholar
• Alcon Inc. Rnai-mediated inhibition of Rho kinase for treatment of ocular disorders. WO2007076367. 2007.
   Google Scholar
• Univ Shenzhen. Application of small-molecule RNA and Rho kinase inhibitor. CN105147714. 2015.
   Google Scholar
• Zeng Y, Zhang X, Kang K, et al. MicroRNA-223 attenuates hypoxia-induced vascular remodeling by targeting RhoB/MLC2 in pulmonary arterial smooth muscle cells. Sci Rep. 2016;28(6):24900.
   Google Scholar
• Univ California. Methods and compositions for treating glaucoma. WO2016134219. 2016.
   Google Scholar
• Bu G. The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int Rev Cytol. 2001;209:79–116.
   PubMedGoogle Scholar
• Luo L, Wall AA, Tong SJ, et al. TLR crosstalk activates LRP1 to recruit Rab8a and PI3Kg for suppression of inflammatory responses. Cell Rep. 2018;24:3033–3044.
   PubMed Web of Science ®Google Scholar